255 related articles for article (PubMed ID: 35306559)
21. Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study.
Xie X; Guo B; Xiao X; Yin J; Wang Z; Jiang X; Li J; Long L; Zhou J; Zhang N; Zhang Y; Chen T; Kangzhuo B; Zhao X
BMC Public Health; 2022 Jan; 22(1):118. PubMed ID: 35038997
[TBL] [Abstract][Full Text] [Related]
22. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
[TBL] [Abstract][Full Text] [Related]
23. Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003-2018.
Xie Z; Aimuzi R; Si M; Qu Y; Jiang Y
Front Public Health; 2023; 11():1133194. PubMed ID: 36950101
[TBL] [Abstract][Full Text] [Related]
24. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations.
Feng Z; Zhao F; Wang Z; Tang X; Xie Y; Qiu L
BMC Gastroenterol; 2024 Mar; 24(1):111. PubMed ID: 38491346
[TBL] [Abstract][Full Text] [Related]
25. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults.
Liu J; Wang G; Wu Y; Guan Y; Luo Z; Zhao G; Jiang Y
Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836318
[TBL] [Abstract][Full Text] [Related]
26. Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China.
Lei F; Wang XM; Wang C; Huang X; Liu YM; Qin JJ; Zhang P; Ji YX; She ZG; Cai J; Li HP; Zhang XJ; Li H
Front Endocrinol (Lausanne); 2023; 14():1109673. PubMed ID: 37082131
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population.
Fan J; Luo S; Ye Y; Ju J; Zhang Z; Liu L; Yang J; Xia M
Nutr Metab (Lond); 2021 Sep; 18(1):82. PubMed ID: 34496912
[TBL] [Abstract][Full Text] [Related]
28. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
29. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
Wei S; Song J; Xie Y; Huang J; Yang J
JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
[TBL] [Abstract][Full Text] [Related]
30. [Performance of users in tropical areas with the BI-RADS classification of breast lesions for predicting malignancy].
Gonsu Kamga JE; Moifo B; Sando Z; Guegang Goudjou E; Nko'o Amvene S; Gonsu Fotsin J
Med Sante Trop; 2013; 23(4):439-44. PubMed ID: 24334372
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.
Kim M; Yoon EL; Cho S; Lee CM; Kang BK; Park H; Jun DW; Nah EH
Liver Int; 2022 Jul; 42(7):1536-1544. PubMed ID: 35338555
[TBL] [Abstract][Full Text] [Related]
32. The Utility of the Fifth Edition of the BI-RADS Ultrasound Lexicon in Category 4 Breast Lesions: A Prospective Multicenter Study in China.
Gu Y; Tian JW; Ran HT; Ren WD; Chang C; Yuan JJ; Kang CS; Deng YB; Wang H; Luo BM; Guo SL; Zhou Q; Xue ES; Zhan WW; Zhou Q; Li J; Zhou P; Zhang CQ; Chen M; Gu Y; Xu JF; Chen W; Zhang YH; Wang HQ; Li JC; Wang HY; Jiang YX
Acad Radiol; 2022 Jan; 29 Suppl 1():S26-S34. PubMed ID: 32768352
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults.
Shi A; Deng J; Ma J; Yang L; Tantai X; Wang Q; Chang D; Wang J; Guo X; Lu X; Shi H
Obes Facts; 2023; 16(6):548-558. PubMed ID: 37640023
[TBL] [Abstract][Full Text] [Related]
34. Probably benign lesions at screening breast US in a population with elevated risk: prevalence and rate of malignancy in the ACRIN 6666 trial.
Barr RG; Zhang Z; Cormack JB; Mendelson EB; Berg WA
Radiology; 2013 Dec; 269(3):701-12. PubMed ID: 23962417
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China.
Li H; Guo M; An Z; Meng J; Jiang J; Song J; Wu W
Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32168920
[TBL] [Abstract][Full Text] [Related]
36. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
[TBL] [Abstract][Full Text] [Related]
37. Comparison of cardiovascular mortality between MAFLD and NAFLD: A cohort study.
Yoo TK; Lee MY; Kim SH; Zheng MH; Targher G; Byrne CD; Sung KC
Nutr Metab Cardiovasc Dis; 2023 May; 33(5):947-955. PubMed ID: 36746687
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China: A cross-sectional study.
He Y; Yao N; Tian F; Liu L; Lin X; Chen X; Duan H; Jiang Y; Yu G; Song C; Wang D; Ma Q; Liu L; Wan H; Shen J
Diabetes Metab Syndr; 2024 Mar; 18(3):102973. PubMed ID: 38493648
[TBL] [Abstract][Full Text] [Related]
39. Risk of malignancy in palpable solid breast masses considered probably benign or low suspicion: implications for management.
Giess CS; Smeglin LZ; Meyer JE; Ritner JA; Birdwell RL
J Ultrasound Med; 2012 Dec; 31(12):1943-9. PubMed ID: 23197547
[TBL] [Abstract][Full Text] [Related]
40. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
